Holen Sie sich die Stockscreener-App
614.78
1.08%
-6.74
Handel nachbörslich:
615.02
0.24
+0.04%
Schlusskurs vom Vortag:
$621.52
Offen:
$620.11
24-Stunden-Volumen:
2.19M
Relative Volume:
2.73
Marktkapitalisierung:
$64.45B
Einnahmen:
$14.92B
Nettoeinkommen (Verlust:
$4.42B
KGV:
14.98
EPS:
41.0422
Netto-Cashflow:
$3.79B
1W Leistung:
-3.77%
1M Leistung:
-10.43%
6M Leistung:
-21.20%
1J Leistung:
+1.55%
1-Tages-Spanne:
$609.77
$624.47
1-Wochen-Bereich:
$609.77
$648.50
52-Wochen-Spanne:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2026-03-06 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | BofA Securities | Underperform → Buy |
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Regeneron Fell 15% Over the Past 30 Days. Here’s What to Expect in 2026 - TIKR.com
Big Biotech Leaders With Established Therapy Strength - Kalkine Media
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
National Pension Service Acquires 82,853 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Fideuram Asset Management Ireland dac Invests $10.12 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Geode Capital Management LLC - MarketBeat
Regeneron Pharmaceuticals (REGN) Receives WHO Approval for Ebola Treatment - GuruFocus
Regeneron (REGN) Advances Maftivimab for Ebola Treatment Trials - GuruFocus
Regeneron Pharmaceuticals' Ebola Antibody Recommended by WHO for Investigational Use in Bundibugyo Ebolavirus - Moomoo
Regeneron, Gilead therapies eyed as potential Ebola treatments by WHO - Seeking Alpha
WHO identifies Ebola treatments, vaccines be tested in trials amid outbreak - Reuters
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak - The Manila Times
WHO prioritizes Regeneron Ebola antibody in Congo and Uganda outbreak trials - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Regeneron Has Fallen 22% Since May. Here’s What the TIKR Model Says About the Upside From Here - TIKR.com
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Notice to Long-Term Shareholders of Commvault Systems, Inc. - GlobeNewswire
Numerous Regeneron Pharmaceuticals Insiders Sold Stock: Not A Positive Omen - Moomoo
Allstate Corp Has $5.92 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Strong Cash Yield: Is Regeneron Pharmaceuticals Stock A Buy? - Trefis
Regeneron to create hundreds of jobs with new Hyderabad GCC - HR Katha
Regeneron Pharmaceuticals, Inc. (REGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
How Low Can REGN Really Go In A Market Crash? - Trefis
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing - The Motley Fool
U.S. biotech giant Regeneron chooses Hyderabad to set up GCC - The Hindu
Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event - Insider Monkey
Important Notice to Long-Term Shareholders of Molina - GlobeNewswire
US biotech giant Regeneron to set up its first Global Capability Centre outside America in Hyderabad - NewsMeter
Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink? - Yahoo Finance
Regeneron Pharmaceuticals to set up Global Capability Centre (GCC) in Hyderabad - Telangana Today
Legal & General Group Plc Sells 27,332 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
US biotech major Regeneron identifies site for its GCC to be operational in 2nd half of 2026 in Hyderabad - Pharmabiz.com
Prospera Financial Services Inc Decreases Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Jefferies Financial Group Inc. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
US Biotech Regeneron to launch Global Capability Centre in Hyderabad - BioSpectrum India
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Trial Wins And New Research Partnership - simplywall.st
US biotech Regeneron to launch global capability centre in India's Hyderabadstatement - marketscreener.com
REGN Stock Price, Quote & Chart | REGENERON PHARMACEUTICALS (NASDAQ:REGN) - ChartMill
Regeneron (REGN) Enters $2.32B Collaboration With Parabilis to Target ‘Undruggable’ Proteins - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) - marketscreener.com
5 Cheap NASDAQ Stocks to Buy Right Now - Insider Monkey
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Simplify Asset Management Inc. - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN): Analyst Ratings Signal Strong Buy with 30% Upside Potential - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire about Securities Investigation - ACCESS Newswire
The week in pharma: action, reaction and insight – week to May 22, 2026 - The Pharma Letter
Why Regeneron (REGN) Is Down 8.5% After Melanoma Trial Miss and New Legal ScrutinyAnd What's Next - simplywall.st
Swedbank AB Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by LSV Asset Management - MarketBeat
Regeneron R&D Updates Test Market View On Long Term Pipeline Value - Yahoo Finance
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
1.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):